Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
STU:WSG's Price-to-Net-Cash is not ranked *
in the Drug Manufacturers industry.
Industry Median: 8.78 * Ranked among companies with meaningful Price-to-Net-Cash only.
China Traditional Chinese Medicine Holdings Co (STU:WSG) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
China Traditional Chinese Medicine Holdings Co Net Cash per Share Related Terms
China Traditional Chinese Medicine Holdings Co Net Cash per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Traditional Chinese Medicine Holdings Co Net Cash per Share Chart
China Traditional Chinese Medicine Holdings Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, China Traditional Chinese Medicine Holdings Co's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Traditional Chinese Medicine Holdings Co Price-to-Net-Cash vs Drug Manufacturers Industry
China Traditional Chinese Medicine Holdings Co Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Traditional Chinese Medicine Holdings Co (STU:WSG) has a Net Cash per Share of €-0.15 as of Dec. 2025. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on China Traditional Chinese Medicine Holdings Co and its competitors. According to the industry distribution chart, China Traditional Chinese Medicine Holdings Co ranks #999999 out of 256 companies in the Drug Manufacturers industry.
Is China Traditional Chinese Medicine Holdings Co's Net Cash per Share too high?
China Traditional Chinese Medicine Holdings Co's current Net Cash per Share is €-0.15. Based on the distribution chart, China Traditional Chinese Medicine Holdings Co ranks #999999 out of 256 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, China Traditional Chinese Medicine Holdings Co has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does China Traditional Chinese Medicine Holdings Co's Net Cash per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Traditional Chinese Medicine Holdings Co ranks #999999 out of 256 companies for Net Cash per Share. This places China Traditional Chinese Medicine Holdings Co in the lower half of its industry. The industry median Net Cash per Share is 8.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Drug Manufacturers company?
The median Net Cash per Share among Drug Manufacturers companies is 8.78, based on 256 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on China Traditional Chinese Medicine Holdings Co and its competitors. For the Drug Manufacturers industry, the median Net Cash per Share is 8.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Traditional Chinese Medicine Holdings Co's current Net Cash per Share is €-0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Traditional Chinese Medicine Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, China Traditional Chinese Medicine Holdings Co (STU:WSG) is currently considered Possible Value Trap. The stock's GF Value™ is €0.27, compared to a current price of €0.14 — trading 48.9% below its estimated fair value. The current Net Cash per Share is €-0.15. China Traditional Chinese Medicine Holdings Co's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For China Traditional Chinese Medicine Holdings Co (STU:WSG), the current Net Cash per Share is €-0.15 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Traditional Chinese Medicine Holdings Co (STU:WSG) Overvalued in 2026?
Based on GuruFocus' analysis, China Traditional Chinese Medicine Holdings Co stock appears to be undervalued.
The current stock price of €0.14 is trading 48.9% below its estimated GF Value™ of €0.27.
GuruFocus considers China Traditional Chinese Medicine Holdings Co to be Possible Value Trap.
Key valuation signals for STU:WSG:
Net Cash per Share: €-0.15
GF Value™: €0.27 vs. price of €0.14 (48.9% below fair value)
No single metric tells the full story. See the STU:WSG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Traditional Chinese Medicine Holdings Co Ltd is engaged in the Chinese healthcare sector. The company functions through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. It generates maximum revenue from the Yifang segment which mainly engages in the manufacture and sales of concentrated TCM granules (CTCMG), TCM healthcare products, and TCM decoction pieces under the Yi Fang brand. The majority of the revenue of the Yi Fang segment is derived from the sales of CTCMG. Geographically, it derives a majority of its revenue from Mainland China, and also has its presence in Hong Kong and Other countries.
50GF Score
Get the complete analysis for STU:WSG
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:WSG has been successfully added to your 
